Crossmark

Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

Crossref DOI link: https://doi.org/10.1007/s12325-022-02047-y

Published Online: 2022-01-30

Published Print: 2022-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sussell, Jesse A. https://orcid.org/0000-0002-9713-8983
Roth, Joshua A.

Meyer, Craig S.

Fung, Anita

Hansen, Svenn A.
Funding

Funding for this research was provided by:

Genentech
License Information

Text and Data Mining valid from 2022-01-30

Version of Record valid from 2022-01-30
More Information

Article History

Received: 30 November 2021

Accepted: 14 January 2022

First Online: 30 January 2022

Change Date: 7 May 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-022-02178-2

Updates are available Correction dated 2022-05-07

Click to view Correction: https://doi.org/10.1007/s12325-022-02178-2